1. Addleman M, Erlichman O, Warr D, Fine S, Murray C (1988) Phase I trial of BRL43694, a 5-HT3 antagonist in the prevention of chemotherapy induced nausea and vomiting (Abstract 297). Proc Am Soc Clin Oncol 7: 77
2. Beecham Pharmaceuticals (March 1988) Clinical Brochure BRL43694A. A novel antiemetic agent
3. Carmichael J, Cantwell B, Edwards C, Harris AL, Coates P, Thompson S, Rapeport G (1988) Phase I and pharmacokinetic study of BRL43694A selective 5HT3 receptor antagonist: effective control of cisplatin induced emesis (Abstract 1082). Proc Am Soc Clin Oncol 7: 279
4. Cassidy J, Lewis C, Adams L, Rapeport WG, Zussman BD, Raina V, Soukop M, Kaye SB (1988) Anti-emetic activity and pharmacokinetics of BRL43694A, a selective 5-HT3 antagonist in cancer chemotherapy (Abstract 1418). Proc Am Assoc Clin Res 29: 356
5. Gumbrell LA, Qualmann C, Perren TJ, Forgeson G, Calvert AH, Thompson S, Rapeport WG (1988) An open pilot study of the 5-HT3 antagonist, BRL43694, an effective antiemetic in refractory highly emetogenic cytotoxic drug induced emesis (Abstract 1149). Proc Am Soc Clin Oncol 7: 296